Scancell Holdings plc has entered into a research collaboration agreement with BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer. The research collaboration will combine Scancell's Moditope immunotherapy platform and BioNTech's platform technology for high-throughput cloning and characterization of naturally selected T cell receptors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
82.52 USD | -2.20% |
|
-4.35% | -21.81% |
06-24 | BioNTech, Duality Biologics Receive FDA Fast-Track Designation for Prostate Cancer Drug | MT |
06-24 | BioNTech Cancer Treatment Gets US FDA Fast Track Designation | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.81% | 19.91B | |
+16.49% | 122B | |
+21.73% | 115B | |
+22.18% | 26.64B | |
-16.89% | 16.32B | |
-18.81% | 15.49B | |
-44.74% | 15.52B | |
+62.72% | 14.83B | |
+3.09% | 13.67B | |
+122.59% | 11.12B |
- Stock Market
- Equities
- BNTX Stock
- News BioNTech SE
- Scancell Holdings plc Enters into Research Collaboration Agreement with Biontech